618-P: Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits

Abstract

Patient perceptions and experiences may explain discrepancies between guideline recommendations and real-world utilization and adherence to cardiorenal protective GLP-1 RAs and SGLT-2is for type 2 diabetes (T2D) . We identified 60,912 posts from public T2D Facebook groups (N=15 from 20to 2021 and extracted all narratives mentioning cardioprotective GLP-1 RAs and SGLT-2is by name (N=250) . We used open coding to categorize all mentions of risks/harms and benefits of these drugs as defined by the 2021 ADA Standards of Care (SOC) vs. described by individuals but not mentioned in the SOC. Individuals reported 41 risks and 6 benefits not in the SOC. Posts rarely (<2.5%) mentioned cardiorenal benefits. Most (62.8%) were information-seeking and posed a question. Numbers of posts mentioning the potential treatment benefits/harms are in Figure 1. Overall, 43.6% of posts mention treatment aspects not discussed in the SOC. People with T2D have a range of concerns and perceptions of the benefits/harms of to GLP-1RAs and SGLT2is. Cardiorenal protection appears to be of lower priority than other tangible benefits/harms. While these data are not representative of all people with T2D (i.e., those underrepresented in social media groups) , they underscore the importance of proactively engaging patients in conversation, eliciting and addressing questions/concerns, and providing evidence-based information on T2D treatment options. Disclosure N.Lambert: Consultant; Hugo Health, Research Support; Optum Labs. C.Clark: Employee; UnitedHealth Group, Stock/Shareholder; UnitedHealth Group. R.G.Mccoy: Consultant; Emmi. A.Wong: Employee; UnitedHealth Group. D.J.Cook: None.